<DOC>
	<DOC>NCT00452790</DOC>
	<brief_summary>The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC) compared to Prevenar (7vPnC), when given concomitantly with routine paediatric vaccinations in India.</brief_summary>
	<brief_title>Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Inclusion Criteria 1. Healthy infants aged 6 weeks (4272 days) at time of enrolment 2. Available for the entire study period Exclusion Criteria 1. Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines 2. A previous anaphylactic reaction to any vaccine or vaccinerelated component 3. Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines</criteria>
	<gender>All</gender>
	<minimum_age>42 Days</minimum_age>
	<maximum_age>72 Days</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Vaccines, Pneumococcal</keyword>
</DOC>